ES2987582T3 - Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan - Google Patents

Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan Download PDF

Info

Publication number
ES2987582T3
ES2987582T3 ES17209399T ES17209399T ES2987582T3 ES 2987582 T3 ES2987582 T3 ES 2987582T3 ES 17209399 T ES17209399 T ES 17209399T ES 17209399 T ES17209399 T ES 17209399T ES 2987582 T3 ES2987582 T3 ES 2987582T3
Authority
ES
Spain
Prior art keywords
biomarkers
diabetes
subject
level
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17209399T
Other languages
English (en)
Spanish (es)
Inventor
Jeffery Cobb
Kirk Lane Pappan
Walter Gall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolon Inc
Original Assignee
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolon Inc filed Critical Metabolon Inc
Application granted granted Critical
Publication of ES2987582T3 publication Critical patent/ES2987582T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
ES17209399T 2013-01-31 2014-01-16 Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan Active ES2987582T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361758924P 2013-01-31 2013-01-31

Publications (1)

Publication Number Publication Date
ES2987582T3 true ES2987582T3 (es) 2024-11-15

Family

ID=51262841

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17209399T Active ES2987582T3 (es) 2013-01-31 2014-01-16 Biomarcadores relacionados con la progresión de la resistencia a la Insulina y métodos que lo utilizan
ES14746017.4T Active ES2669620T3 (es) 2013-01-31 2014-01-16 Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14746017.4T Active ES2669620T3 (es) 2013-01-31 2014-01-16 Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan

Country Status (5)

Country Link
US (2) US9910047B2 (enExample)
EP (2) EP2951313B1 (enExample)
JP (1) JP6404834B2 (enExample)
ES (2) ES2987582T3 (enExample)
WO (1) WO2014120449A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014243259B2 (en) * 2013-03-28 2019-04-18 Société des Produits Nestlé S.A. Indoxyl sulfate as a biomarker of prebiotic efficacy for weight gain prevention
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
CN109154619A (zh) * 2016-05-17 2019-01-04 国立大学法人大阪大学 用于判定糖尿病的血液试样的分析方法及系统
EP3465202B1 (en) 2016-06-02 2023-07-05 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
ES3004083T3 (en) * 2016-12-19 2025-03-11 Metabolon Inc Mass spectrometry assay method for detection and quantitation of kidney function metabolites
WO2018150077A1 (en) * 2017-02-16 2018-08-23 Afekta Technologies Oy Betaine biomarkers for nutritional status, nutritional regimen, endogenous metabolism, or risk of cardiovascular or metabolic diseases
JP7337701B2 (ja) * 2017-03-31 2023-09-04 クエスト ダイアグノスティックス インヴェストメンツ エルエルシー インスリン及びｃ－ペプチドの定量の方法
EP3401683A1 (en) * 2017-05-10 2018-11-14 Eberhard Karls Universität Tübingen Medizinische Fakultät Diagnosing metabolic disease by the use of a biomarker
EP3740200B1 (en) * 2018-01-17 2024-12-11 University Of Southampton Methods to predict risk of and to stratify sarcopenia and nad deficiency
US20210396766A1 (en) * 2018-09-27 2021-12-23 Societe Des Produits Nestle S.A. Markers of risk to develop insulin resistance during childhood and young adulthood
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
KR102231928B1 (ko) * 2019-09-19 2021-03-26 고려대학교 산학협력단 비만대사수술 이후 당뇨병 예후 예측용 바이오마커 조성물
CA3177108A1 (en) * 2020-04-27 2021-11-04 Wayne R. Matson Detection and modification of gut microbial population
CN112149311B (zh) * 2020-10-12 2021-10-26 北京中恒利华石油技术研究所 一种基于数量规约的非线性多元统计回归测井曲线预测方法
CN112843036A (zh) * 2021-01-29 2021-05-28 中国药科大学 β-羟基丙酮酸在制备人胰岛淀粉样多肽聚集抑制剂中的应用
CN116087486B (zh) * 2021-11-08 2024-02-02 中国医学科学院阜外医院 糖尿病患者早期预测心血管疾病（cvd）的生物标志物及其用途
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
EP4504961A1 (en) * 2022-04-07 2025-02-12 Need4Health B.V. Method for determining insulin dosage
JP7736971B2 (ja) * 2022-10-18 2025-09-10 株式会社オルトメディコ 糖尿病境界域者のスクリーニング方法
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
EP1718327B1 (en) 2003-06-20 2015-01-07 University of Florida Biomarkers for differentiating between type 1 and type 2 diabetes
US7682782B2 (en) 2004-10-29 2010-03-23 Affymetrix, Inc. System, method, and product for multiple wavelength detection using single source excitation
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
ES2525345T3 (es) * 2006-03-24 2014-12-22 Metanomics Gmbh Procedimiento de diagnóstico de diabetes de tipo II
EP2164977B1 (en) * 2007-07-17 2013-10-30 Metabolon, Inc. Biomarkers for pre-diabetes and methods using the same
US20110311650A1 (en) 2008-07-07 2011-12-22 Thomas Wang Multiplexed biomarkers of insulin resistance
EP2313773A1 (en) * 2008-07-15 2011-04-27 Metanomics Health GmbH Means and methods diagnosing gastric bypass and conditions related thereto
US20120122981A1 (en) 2009-03-31 2012-05-17 Yun Fu Hu Biomarkers Related to Insulin Resistance and Methods using the Same
US8367418B2 (en) 2009-10-23 2013-02-05 Therasyn Sensors, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
EP2494364A1 (en) 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
US20140303228A1 (en) * 2011-10-18 2014-10-09 Metabolon, Inc. Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same
US20150065366A1 (en) * 2011-11-11 2015-03-05 Metabolon, Inc. Biomarkers for Bladder Cancer and Methods Using the Same
AU2012347557A1 (en) * 2011-12-09 2014-07-03 Metabolon, Inc. Biomarkers for kidney cancer and methods using the same

Also Published As

Publication number Publication date
EP2951313A1 (en) 2015-12-09
JP2016509222A (ja) 2016-03-24
US20150362510A1 (en) 2015-12-17
JP6404834B2 (ja) 2018-10-17
EP3321686A1 (en) 2018-05-16
HK1217516A1 (en) 2017-01-13
US9910047B2 (en) 2018-03-06
EP2951313B1 (en) 2018-03-07
US20180203021A1 (en) 2018-07-19
EP3321686B1 (en) 2024-03-13
EP2951313A4 (en) 2016-11-02
WO2014120449A1 (en) 2014-08-07
ES2669620T3 (es) 2018-05-28

Similar Documents

Publication Publication Date Title
ES2669620T3 (es) Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan
Wolak-Dinsmore et al. A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness
Tu et al. Serum 25-hydroxyvitamin D predicts the short-term outcomes of Chinese patients with acute ischaemic stroke
Chonchol et al. Relationship of uric acid with progression of kidney disease
ES2443540T3 (es) Biomarcadores para pre-diabetes y métodos que usan los mismos
US10302663B2 (en) Method of assessing pancreatic beta-cell function
Kunutsor et al. Plasma calprotectin and risk of cardiovascular disease: Findings from the PREVEND prospective cohort study
Owens et al. An integrated biochemical prediction model of all-cause mortality in patients undergoing lower extremity bypass surgery for advanced peripheral artery disease
EP2414535A1 (en) Biomarkers related to insulin resistance and methods using the same
Ye et al. Building and verifying a severity prediction model of acute pancreatitis (AP) based on BISAP, MEWS and routine test indexes
EP2222220A1 (en) Trimethylamine compounds as risk predictors of cardiovascular disease
CN105026935B (zh) 异戊酰甘氨酸作为增重和肥胖倾向的生物标志物
Tuomisto et al. A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts
Kuo et al. Age and sex differences in the relationship between neutrophil-to-lymphocyte ratio and chronic kidney disease among an adult population in Taiwan
Ottas The metabolomic profiling of psoriasis, atopic dermatitis and atherosclerosis
Mosterd et al. Plasma and urine metabolites associated with nondiabetic chronic kidney disease: the HELIUS study
CN118866120B (zh) 预测脓毒症患者死亡高风险的生物标志物、系统及其应用
La Sala et al. One-hour plasma glucose combined with skin autofluorescence identifies subjects with pre-diabetes: the DIAPASON study
Murphy et al. Clinical outcomes following burn injury across the continuum of chronic glycemic control
Busto et al. A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification
Ackermans et al. Serum metabolomics analysis for quantification of muscle loss in critically ill patients: an explorative study
CN118806773B (zh) Udca系列胆汁酸在预防脓毒症肠道炎症损伤中的作用机制及其应用
Petersson Exploring Metabolic and Functional Changes in Stroke Patients: Insights from a Urinary and Blood-Derived Metabolomic Study
Larsson et al. Reference values for fasting insulin in 75 year old females and males
Saini et al. Urinary biomarkers in metabolic syndromes